Oncurious is a new oncology company that will perform clinical trials for the development of TB-403. This compound is a new promising agent for the treatment of brain tumors in children. Alongside ThromboGenics, VIB (Flemish Institute for Biotechnology) will be a shareholder.
Medulloblastoma is a rare, but life-threatening, brain tumor that occurs mostly in children. In this type of cancer, PLGF (placental growth factor) is (over-)expressed. TB-403 is a monoclonal antibody directed against PLGF. Animal studies were promising and the safety profile is favorable. TB-403 also has potential as a treatment for other pediatric tumours. Johan Cardoen, executive at VIB, hopes to make Oncurious into a leading oncology company.
Read more about this topic in our soon to be published Insights article.
